Avidity Biosciences Unveils Stock Option Grant for New CTO

Avidity Biosciences Announces Stock Option Grant for New CEO

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company focused on pioneering RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), recently made an important announcement. The Human Capital Management Committee of Avidity's Board of Directors has granted Charles Calderaro III, the new Chief Technical Officer, a stock option award and restricted stock units reflecting the company's commitment to innovation and talent acquisition.

The Inducement Grants and Their Significance

On a significant day marked by this decision, Avidity Biosciences granted Mr. Calderaro a non-qualified stock option award to purchase a total of 80,000 shares of its common stock alongside 40,000 restricted stock units. These awards were issued as material inducements to entice Mr. Calderaro to join the company, which is in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan is designed specifically to provide equity awards to new hires who are new to Avidity or returning after a bona fide break in employment. This strategic move underscores Avidity's drive to attract top talent into critical roles that can shape the future of RNA therapeutics.

Details of the Stock Option and Restricted Stock Units

The awarded stock option comes with an exercise price set at $31.42 per share, aligning with Avidity's closing stock price on the Nasdaq Global Market on January 6, 2025. The structure of the award is crafted to serve both as a measure of value and a motivator. The option stock will vest over a four-year period, with an initial 25% vesting on the first anniversary of employment, followed by monthly vesting for the next three years, provided Mr. Calderaro remains with Avidity during these times.

In addition, the RSUs will also vest over a four-year timeframe, with equal installments on each anniversary of the vesting commencement date. This structured approach ensures that both Mr. Calderaro's interests and Avidity's growth are aligned, creating a strong incentive for performance and commitment.

Avidity's Vision and Commitment to Innovation

At Avidity Biosciences, the core mission focuses on enhancing human health through the development of revolutionary RNA-based therapies. Utilizing its proprietary AOCs, Avidity is on a mission to deliver effective treatments that combine the specificity of monoclonal antibodies with highly precise oligonucleotide therapies. This innovative approach aims to tackle diseases that have long evaded effective treatment.

Currently, Avidity is at the forefront of developing solutions for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). These initiatives not only showcase Avidity's dedication to advancing medical science but also the potential of AOCs to transform the landscape of RNA therapeutics.

Future Endeavors and Partnerships

Avidity's commitment to exploration doesn’t stop at neuromuscular diseases. The company is also progressing two wholly-owned precision cardiology candidates that target rare genetic cardiomyopathies. Furthermore, the company is extending its AOC technology into the realms of cardiology and immunology through strategic partnerships. This expansion is part of Avidity's broader goal to enhance the reach and impact of its innovative therapies across multiple therapeutic areas.

About Avidity Biosciences

Avidity Biosciences, Inc. aims to revolutionize RNA therapies through its unique AOCs. These therapies are not only designed to deliver RNA to targeted locations in the body but also to integrate precision and efficacy, addressing previously unmet medical needs. Headquartered in a vibrant and innovative hub, Avidity continues to connect and collaborate with researchers and industry leaders to foster advancements in healthcare.

Investor and Media Contacts

For inquiries related to investor relations, individuals can reach out to Kat Lange at (619) 837-5014. For media-related questions, Di Andrews can be contacted at (619) 837-5016.

Frequently Asked Questions

What is the significance of the stock option grant?

The stock option grant to Charles Calderaro III illustrates Avidity Biosciences' commitment to attracting top talent and aligns employee incentives with company performance.

What are Antibody Oligonucleotide Conjugates (AOCs)?

AOCs are a new class of RNA therapeutics combining monoclonal antibodies with oligonucleotide therapies to target diseases that traditional RNA therapies cannot.

What diseases are Avidity targeting with its therapies?

Avidity is focusing on three rare neuromuscular diseases: myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.

How does the vesting schedule work for the awarded options?

The stock options vest over four years, with 25% vesting on the first anniversary, followed by monthly vesting over the remaining period.

What role does Avidity aim to play in the future of RNA therapies?

Avidity intends to lead the market by developing targeted RNA therapies that offer new solutions for conditions currently without effective treatments.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.